ClinicalTrials.gg
RecruitingNCT03649880Updated Sep 18, 2026

Feasibility of FMISO in Brain Tumors

A Phase 2 interventional study of ¹⁸F-Fluoromisonidazole and Computed Tomography in IDH Wild Type Glioblastoma, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by OHSU Knight Cancer Institute · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2019; still recruiting 7 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 323 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
225th of 1,155
77 · median 33
Started
2019
with 48 others
Phase 2
396 of 1,302
37 open now
Primary completion
2029-01
later than 257 of 321 live
Registered
876th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 225th largest by planned enrollment of the 1,155 interventional ones that give a count, is one of 49 that started in 2019, is one of 396 in phase 2, reaches primary completion later than 257 of the 321 other live ones, and was the 876th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 341 Glioblastoma studies recruiting now, 236 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

This phase II trial studies how well 18F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. Two contrast agents called gadolinium and ferumoxytol are used during some of the MRI scans. A contrast agent is a liquid-like dye that is given intravenously (IV) to help imaging machines create pictures. The study drug, called FMISO, provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine the feasibility of obtaining 18F-fluoromisonidazole (FMISO) PET (hypoxic volume and tumor to blood background values [T/B]) and dynamic susceptibility contrast enhanced (DSC), diffusion-weighted imaging (DWI), \& segregation \& extravascular localization of ferumoxytol imaging (SELFI) MRI measures in patients with intracranial brain tumors.

II. Determine if MRI contrast-enhancement and hypoxic volume are imaging profiles of glioblastoma immunotherapy-mediated pseudoprogression or true progression in a clinical trial.

III. Determine if SELFI hypoxic fraction are imaging biomarkers of glioblastoma neuroinflammation.

SECONDARY OBJECTIVES:

I. Determine the feasibility of baseline and follow-up ferumoxytol (Fe)-enhanced FMISO PET and MR imaging co-registration.

II. Assess diagnostic performance of imaging metrics to identify failed therapy at earlier imaging timepoints before presumed progression.

III. Determine the reliability of the pre-therapy FMISO PET imaging metrics as assessed by baseline "test" and "retest experiments.

IV. Compare the diagnostic performance of SELFI hypoxic fraction to Modified Response Assessment in Neuro-Oncology (mRANO) criteria.

V. Determine the sensitivity and specificity of SELFI hypoxic fraction for the diagnosis of neuroinflammation and recurrent disease.

VI. Assess progression free survival. VII. Assess overall survival. VIII. Determine change in imaging metrics from post-therapy and disease progression in differentiating neuroinflammation from recurrent disease.

IX. Determine optimal SELFI hypoxic fraction imaging parameters. X. Correlate SELFI hypoxic fraction with innate immune phenotype and hypoxia expression.

TERTIARY OBJECTIVE:

I. Determine the reproducibility of the baseline FMISO PET imaging metrics as assessed by baseline "test" and "retest" experiments.

OUTLINE:

Participants receive FMISO and/or FE IV. Patients also undergo dynamic PET/computed tomography (CT) or PET/MRI over 120 minutes beginning 1 minute prior to FMISO injection, and static PET/CT or PET/MRI over 20-40 minutes approximately 90 minutes after FMISO injection. Participants may then receive FMISO and/or Fe IV and gadolinium IV and undergo PET/MRI scan, followed by an additional PET/MRI scan without FMISO and/or Fe and gadolinium the following day. These scans may repeat every 4 weeks up to 4 times. Supplemental oxygen may be administered to affect MRI signal change.

After conclusion of the diagnostic tests, participants are followed for up to 5 years.

03

Conditions studied

  • IDH Wild Type Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (18 years of age and older) with a clinically suspected glioma
  • Able to provide informed written consent and/or acceptable surrogate capable of providing consent on the patient's behalf
  • Legally authorized representative (LAR)-signed and assent obtained for those subjects identified as decisionally impaired
  • Intracranial disease greater than 5 mL as assessed by T2/fluid attenuated inversion recovery (FLAIR) MR imaging
  • performance score > 60 or (ECOG) \< 3 as assessed by referring clinician.
  • Either has previously received therapeutic intervention for an intracranial tumor or is eligible for and agreeable to receiving standard of care stupp protocol radiation and temozolomide after or maximum safe surgical resection
  • of at least 6 months
  • Female subject of will be asked for possibility of pregnancy. If unsure of pregnancy status, then a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study drug (FMISO). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Adequate organ function as demonstrated by a chart review of , renal, hepatic, and coagulation. We will follow the Department of Diagnostic Radiology clinical policy for assessing renal function prior to injecting gadolinium-based contrast. If there is a history of poor kidney function, a point of care serum creatinine test may be performed to ensure adequate kidney function prior to FMISO administration. If there is a history of any other poor organ function, we will not administer Ferumoxytol, but the subject may receive all other study interventions

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding.
  • to PET, MRI, FMISO, ferumoxytol, or intravenous gadolinium based contrast agents.
  • Claustrophobia is not controlled with medical therapy
  • Weight is greater than modality maximum capacity.
  • Presence of metallic foreign body or implanted medical devices in body not documented as MRI safe according to the Oregon Health \& Science University (OHSU) Department of Radiology guidelines (including but not limited to cardiac pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants).
  • Subjects with family history of or known iron overload (genetic hemochromatosis).
  • Subject who have received ferumoxytol within 3 weeks of study entry and require another ferumoxytol administration.
  • Subjects with three or more drug allergies from separate drug classes.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to FMISO. An allergic reaction to nitroimidazoles is highly unlikely.
  • Sickle cell disease.
  • History of hypersensitivity allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or gadolinium MRI contrast
  • Unsure of pregnancy status as assessed by Department of Radiology and AIRC guidelines.
  • Subjects for whom supplemental oxygen could be harmful such as people with potential for hypoventilation (end-stage [COPD], obstructive sleep apnea [OSA] on continuous positive airway pressure [CPAP]/biphasic positive airway pressure [Bi-PAP], etc).
  • Presence of any other co-existing condition that, in the judgment of the principal investigator, might increase the risk to the subject (i.e., plans for hospice or end of life care).
  • Poor peripheral intravenous access evaluated by patient history.
  • Presence of other serious systemic illnesses, including: uncontrolled infection, other uncontrolled , uncontrolled diabetes type II, or psychiatric/social situations which might impact the endpoint of the study or limit compliance with study requirements.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
77 participants (estimated)

Study arms

  • Experimental
    Diagnostic (FMISO, PET/MRI or PET/CT)

    Participants receive FMISO and/or FE IV. Patients also undergo dynamic PET/CT or PET/MRI over 120 minutes beginning 1 minute prior to FMISO injection, and static PET/CT or PET/MRI over 20-40 minutes approximately 90 minutes after FMISO injection. Participants may then receive FMISO and/or Fe IV and gadolinium IV and undergo PET/MRI scan, followed by an additional PET/MRI scan without FMISO and/or Fe and gadolinium the following day. These scans may repeat every 4 weeks up to 4 times. Supplemental oxygen may be administered to affect MRI signal change.

    Drug: ¹⁸F-Fluoromisonidazole · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Procedure: Oxygen Therapy · Drug: Ferumoxytol · Drug: Gadolinium

Interventions

  • DrugFluoromisonidazoleStudies of FluoromisonidazoleFluoromisonidazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: ¹⁸F-MISO, ¹⁸F-Misonidazole, FMISO

  • ProcedureComputed Tomography

    Undergo PET/CT

    Also known as: CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography

  • ProcedureMagnetic Resonance Imaging

    Undergo PET/MRI or PET/CT

    Also known as: Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), NMRI, Nuclear Magnetic Resonance Imaging

  • ProcedurePositron Emission Tomography

    Undergo PET/MRI

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging

  • ProcedureOxygen Therapy

    Receive supplemental oxygen

    Also known as: supplemental oxygen therapy

  • DrugFerrosoferric OxideStudies of Ferrosoferric OxideFerrosoferric Oxide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Feraheme, Ferumoxytol, ferumoxytol, FERUMOXYTOL NON-STOICHIOMETRIC MAGNETITE, Ferumoxytol Non-Stoichiometric Magnetite

  • DrugGadolinium

    Given IV

06

What researchers measure

Primary outcomes

  1. Successful production of images

    Assessed as a factor of generating quantitative positron emission tomography (PET)/magnetic resonance imaging (MRI) metrics (intra-tumoral FMISO tumor to blood \[T/B\] level, hypoxic volume, dynamic susceptibility contrast enhanced \[DSC\], diffusion-weighted imaging \[DWI\], and segregation \& extravascular localization of ferumoxytol imaging \[SELFI\] values, and tissue oxygen maps). Images generated during the administration of oxygen will be used to generate tissue oxygen maps of the brain. Following completion of cohort enrollment, the generation of each quantitative PET/MRI metric will be independently scored as a dichotomous variable; successful or non-successful. Proportional assessment will be performed to assess for project feasibility. The estimated proportion of success rate for each metric along with the corresponding 95% binomial confidence interval will be provided.

    Time frame: Two days of diagnostic imaging

  2. SELFI and hypoxic fraction, and T1 ferumoxytol Fe/gadolinium (Gd) log mismatch ratio in patients receiving immunotherapy

    Diagnostic performance of PET/MRI metrics (SELFI and hypoxic fraction) and Gd\_MRI to differentiate progression from neuroinflammation (pseudoprogresion) will be evaluated using sensitivity, specificity and area under the receiver operating curve (AUROC). Sensitivity and specificity will be characterized using proportions and exact 95% confidence intervals. Difference in diagnostic performance between PET/MRI metrics (SELFI and hypoxic fraction) and Gd\_MRI will be assessed using McNemar's test to compare sensitivity and specificity and using the DeLong test to compare AUROC.

    Time frame: Two days of diagnostic imaging at time of suspected progression

  3. SELFI and hypoxic fraction, and T1 ferumoxytol Fe/gadolinium (Gd) log mismatch ratio in all patients

    Diagnostic performance of PET/MRI metrics (SELFI and hypoxic fraction) and Gd\_MRI to differentiate progression from neuroinflammation (pseudoprogresion) will be evaluated using sensitivity, specificity and AUROC. Sensitivity and specificity will be characterized using proportions and exact 95% confidence intervals. Difference in diagnostic performance between PET/MRI metrics (SELFI and hypoxic fraction) and Gd\_MRI will be assessed using McNemar's test to compare sensitivity and specificity and using the DeLong test to compare AUROC.

    Time frame: Two days of diagnostic imaging at time of suspected progression

Secondary outcomes

  1. Successful co-registration (Yes vs. No)

    The generation of co-registered imaging data sets will be independently scored as a dichotomous variable; successful or non-successful (\< 10mm versus \[vs.\] \> 10mm alignment error). Proportional assessment will be performed to assess for project feasibility. The estimated proportion along with the corresponding 95% binomial confidence interval will be provided.

    Time frame: Baseline to the start of long-term follow-up (up to 5 years)

  2. T/B value and hypoxic tumor volume

    Tumor-to-background ratio (TBR) is calculated by dividing the tumor SUV by the mean SUV of the background region, using either voxelwise values or summary measures such as SUVmean. To define hypoxic volume, a threshold-based approach is applied in which all tumor voxels with FMISO uptake above a predetermined TBR cutoff are classified as hypoxic; the hypoxic volume is then calculated as the total volume of these above-threshold voxels. Hypoxic volume is measured in mm3.

    Time frame: Time Frame: Baseline to the start of long-term follow-up (up to 5 years)

  3. Generation of SELFI Metric

    Will assess generation of whole brain SELFI MRI data set. Generation of SELFI MRI: YES/NO.

    Time frame: Imaging time points before gadolinium-based contrast agent defined presumed progression, year 1-4

  4. SELFI diagnostic performance of imaging metrics

    SELFI metric will be assessed to identify failed therapy at each imaging timepoint. Assessing Failed Therapy: Area Under the Curve for each metric at each time point to diagnose disease progression

    Time frame: Imaging time points before gadolinium-based contrast agent defined presumed progression, year 1-4

  5. Generation of Hypoxic Fraction Metric

    Will assess generation of hypoxic fraction data set. Generation of hypoxic fraction: MRI YES/NO.

    Time frame: Imaging time points before gadolinium-based contrast agent defined presumed progression, year 1-4

  6. Hypoxic Fraction Diagnostic performance of imaging metric

    Hypoxic Fraction metric will be assessed to identify failed therapy at each imaging timepoint. Assessing Failed Therapy: Area Under the Curve for each metric at each time point to diagnose disease progression.

    Time frame: Imaging time points before gadolinium-based contrast agent defined presumed progression, year 1-4

  7. Hypoxic fraction

    Will determine the reproducibility of the pre-therapy FMISO PET imaging metrics as assessed by baseline "test" and "retest experiments. Reproducibility of hypoxic fraction between baseline "test" and "retest experiments will be evaluated by intra-class correlation coefficients (ICC).

    Time frame: Retest will be scheduled within 7 days after the initial PET imaging examination, Baseline, year 1-4]

  8. SELFI, hypoxic fraction and Modified Response Assessment in Neuro-Oncology (mRANO) criteria

    Sensitivity, specificity and AUROC will be used to determine the diagnostic performance of imaging biomarkers (SELFI and hypoxic fraction, change in SELFI and hypoxic fraction between fraction between post-radiation therapy and suspected disease progression) and mRANO to differentiate progression from neuroinflammation (pseudoprogresion). Optimal cutoff points for SELFI and hypoxic fraction will be identified. Sensitivity and specificity will be characterized using proportions and exact 95% confidence intervals. McNemar's test will be used to compare sensitivity and specificity between imaging biomarkers and mRANO. Comparison of diagnostic performance with Gd MRI may also be explored.

    Time frame: Year 1-5 at suspected disease progression

  9. SELFI and hypoxic fraction

    Will determine the sensitivity and specificity of SELFI hypoxic fraction for the diagnosis of neuroinflammation and recurrent disease. Sensitivity and specificity will be characterized using proportions and exact 95% confidence intervals. McNemar's test will be used to compare sensitivity and specificity between imaging biomarkers and mRANO. Comparison of diagnostic performance with Gd MRI may also be explored.

    Time frame: Year 1-5 at suspected disease progression

  10. Progression free survival (PFS)

    Will be analyzed using the Kaplan-Meier product limit methods for all patients, taking censoring into account. A Cox regression model will be used to explore the association between imaging biomarkers and PFS while adjusting for patient characteristics.

    Time frame: Date of diagnosis to date of progression, death or end of study, assessed up to 5 years

  11. Overall survival (OS)

    Will be analyzed using the Kaplan-Meier product limit methods for all patients, taking censoring into account. A Cox regression model will be used to explore the association between imaging biomarkers and OS while adjusting for patient characteristics.

    Time frame: Date of diagnosis to date of progression, death or end of study, assessed up to 5 years

  12. Change in SELFI and hypoxic fraction

    Difference of SELFI or hypoxic fraction between post-radiation therapy and suspected disease progression

    Time frame: From post-therapy to disease progression/pseudoprogression, year 1-5

  13. SELFI

    Will determine optimal SELFI imaging parameters. Outcome Measure: Optimal SELFI imaging echo time (TE) and repetition time (TR). Description: The optimal SELFI imaging parameters will be defined as the echo time (TE) and repetition time (TR) combination that demonstrates the highest correlation coefficient between SELFI and macrophage cellular density measured in tumor tissue samples. Unit of Measure: Milliseconds (ms).

    Time frame: Baseline at year 1-3

  14. SELFI and hypoxic fraction

    Will assess correlation of SELFI hypoxic fraction with innate immune phenotype and hypoxia expression. Since innate immune phenotype is a binary variable (M1, or M2), differences in imaging metrics between M1 and M2 will be evaluated using two sample t-test. If normal assumption is not satisfied, data transformation, or 95% confidence intervals based on bootstrapping method will be used. Hypoxia expression will be measured by an ordinal variable (0,1,2,3,4) based on CA-9 expression, and correlation between SELFI/hypoxic fraction and hypoxia expression will be evaluated by Spearman's rank correlation coefficient.

    Time frame: Year 1-4

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Jan 2029, 115 months after the start.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 115 months is above that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2018
First posted
Aug 28, 2018
StartActual
Jun 1, 2019
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2030
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03649880
Responsible party
Ramon Barajas (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Aug 28, 2018
Start date
Jun 1, 2019
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Sep 18, 2026

Study contacts

Ramon Barajas
principal investigator · OHSU Knight Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluoromisonidazole

Start the discussion